<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00782145</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000613668</org_study_id>
    <secondary_id>R01CA119196</secondary_id>
    <secondary_id>TUFTS-8338</secondary_id>
    <secondary_id>WCCC--2007-1357</secondary_id>
    <secondary_id>CHW-07237</secondary_id>
    <secondary_id>CHW-GC-580</secondary_id>
    <secondary_id>DFCI-08-106</secondary_id>
    <secondary_id>CHNMC-08009</secondary_id>
    <secondary_id>CCHMC-0002988</secondary_id>
    <secondary_id>FHCRC-2210</secondary_id>
    <nct_id>NCT00782145</nct_id>
  </id_info>
  <brief_title>A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families</brief_title>
  <official_title>HSCT-CHESS to Enhance Hematopoietic Transplant Recovery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tufts Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Tufts Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: A Web site for stem cell transplant health information and support may be&#xD;
      effective in helping parents improve their health-related knowledge, skills, and quality of&#xD;
      life, which may also improve their children's quality of life.&#xD;
&#xD;
      PURPOSE: This randomized phase III trial is studying a Web-based stem cell transplant support&#xD;
      system to see how well it works compared with standard care in families of young patients&#xD;
      undergoing a stem cell transplant.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To evaluate the ability of a Web-based Hematopoietic Stem Cell Transplantation (HSCT-)&#xD;
           Comprehensive Health Enhancement Support System (HSCT-CHESS) to mitigate the impact of a&#xD;
           child's HSCT on the health-related quality of life, family functioning, knowledge,&#xD;
           skills, and processes of care of the accompanying parent.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To explore the potential mechanisms of action of HSCT-CHESS in improving outcomes in&#xD;
           these parents, in terms of parental activation, social support and/or coping skills.&#xD;
&#xD;
        -  To explore the impact of HSCT-CHESS on the health-related quality of life of the&#xD;
           pediatric HSCT patient, as reported by the parent and child.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Pediatric hematopoietic stem cell transplantation&#xD;
      (HSCT) recipients (ages 2 months-18 years) and accompanying parents are asked to complete a&#xD;
      baseline assessment battery by the start of transplant conditioning (the 'run-in' period). If&#xD;
      either member of the participating dyad fails to complete all study measures* during this&#xD;
      time period, the dyad is withdrawn from the study. The dyads are randomized into 1 of 2&#xD;
      intervention arms.&#xD;
&#xD;
      NOTE: *Measures will not be collected from pediatric patients under 5 years of age at&#xD;
      baseline or follow-up.&#xD;
&#xD;
        -  Arm I: Each dyad receives institution-specific usual care for 6 months, which typically&#xD;
           includes psychosocial support for the HSCT recipient and individualized or group&#xD;
           education and support for the accompanying parent during the peri-transplant period.&#xD;
           They also receive the Web-based Hematopoietic Stem Cell Transplantation (HSCT-)&#xD;
           Comprehensive Health Enhancement Support System (HSCT-CHESS) intervention for 6 months.&#xD;
           Accompanying parents also may identify a companion to receive access to the HSCT-CHESS&#xD;
           Web site.&#xD;
&#xD;
      The HSCT-CHESS Web site provides ready access to accurate information and resources about&#xD;
      pediatric HSCT, practical tips, organizational tools, and other supportive services for use&#xD;
      during the transplant process. While the Web site is designed primarily for use by the&#xD;
      accompanying parent, it also includes some resources for child and adolescent HSCT recipients&#xD;
      that the parent may choose to share. In addition to collecting data for later analysis, the&#xD;
      Web site tracking system allows for further tailoring of information and support for the&#xD;
      user, principally by time post transplant.&#xD;
&#xD;
        -  Arm II: Each dyad receives institution-specific usual care for 6 months as described in&#xD;
           arm I. Accompanying parents also receive a book from the Blood and Marrow Transplant&#xD;
           Information Network (BMT InfoNet).&#xD;
&#xD;
      Each dyad completes quality-of-life assessment (Child Health Ratings Inventory&#xD;
      [CHRIs]-General and CHRIs-HSCT) at day 45, and at 3, 6, 9, and 12 months and CHRIS-General at&#xD;
      baseline. The accompanying parent provides demographic information at baseline and 6 months&#xD;
      and completes Patient Health Questionnaire (PHQ-9) for depression screening at baseline and 6&#xD;
      and 9 months. The accompanying parent also completes other measures for family and individual&#xD;
      coping, social support, process of care, and Internet use at baseline and 6 and 9 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of the Hematopoietic Stem Cell Transplantation Comprehensive Health Enhancement Support System (HSCT-CHESS) on health-related quality of life of the accompanying parent at study entry, day 45 and 3, 6, 9, and 12 months</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of HSCT-CHESS on family functioning as reported by the accompanying parent at study entry, 6, and 9 months</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of HSCT-CHESS on accompanying parent's knowledge and skills in caring for self and the HSCT recipient, increased confidence interacting with health care provider(s) and greater healthcare participation at study entry, 6, and 9 months</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Potential mechanisms of action of HSCT-CHESS in improving parental activation, social support and/or coping skills at study entry and 6 and 9 months</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life of the patient as reported by both parent and child at study entry, day 45, 3, 6, 9, and 12 months</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">198</enrollment>
  <condition>Chronic Myeloproliferative Disorders</condition>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Myelodysplastic/Myeloproliferative Neoplasms</condition>
  <condition>Neuroblastoma</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Psychosocial Effects of Cancer and Its Treatment</condition>
  <condition>Sarcoma</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each dyad receives institution-specific care for 6 months, which typically includes psychosocial support for the HSCT recipient and individualized or group education and support for the accompanying parent during the peri-transplant period. They also receive the Web-based Hematopoietic Stem Cell Transplantation (HSCT-) Comprehensive Health Enhancement Support System (HSCT-CHESS) intervention for 6 months. Accompanying parents also identify a companion to receive access to the HSCT-CHESS Web Site.&#xD;
The HSCT-CHESS Web site provides ready access to accurate information and resources about pediatric HSCT, practical tips, organizational tools, and other supporting services for use during the transplant process. In addition to collecting data for later analysis, the Web site tracking system allows for further tailoring of information and support for the user, principally by time post transplant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each dyad receives institution-specific usual care for 6 months as described in arm I. Accompanying parents also receive a book from the Blood and Marrow Transplant Information Network (BMT Infonet).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>educational intervention</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>informational intervention</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>internet-based intervention</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>questionnaire administration</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>study of socioeconomic and demographic variables</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>survey administration</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>psychosocial assessment and care</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>quality-of-life assessment</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>standard follow-up care</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Disease indications for hematopoietic stem cell transplantation (HSCT)&#xD;
&#xD;
               -  All transplant types allowed&#xD;
&#xD;
          -  Scheduled to receive HSCT within the next 30 days&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Dyad consisting of age-eligible child and parent&#xD;
&#xD;
          -  Child patient with an &quot;accompanying parent&quot; who consents to participate&#xD;
&#xD;
               -  &quot;Accompanying parent&quot; is defined as the parent/legal guardian who physically&#xD;
                  stays with the recipient during the initial HSCT hospitalization and plans to be&#xD;
                  present during the follow-up assessments&#xD;
&#xD;
                    -  If the responsibility for care giving is shared, parents will designate who&#xD;
                       will participate (i.e., as study participant)&#xD;
&#xD;
                         -  No substitutions are permitted once this decision has been made&#xD;
&#xD;
               -  Accompanying parent must be â‰¥ 18 years old&#xD;
&#xD;
          -  Possesses a working knowledge of English&#xD;
&#xD;
          -  Able to sign consent/assent to participate&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No concurrent participation in another quality-of-life intervention study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan K. Parsons, MD, MRP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tufts Medical Center Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010-3000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin Cancer Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <study_first_submitted>October 29, 2008</study_first_submitted>
  <study_first_submitted_qc>October 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2008</study_first_posted>
  <last_update_submitted>July 11, 2011</last_update_submitted>
  <last_update_submitted_qc>July 11, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 13, 2011</last_update_posted>
  <responsible_party>
    <name_title>Susan Kenyon Parsons</name_title>
    <organization>Tufts Medical Center Cancer Center</organization>
  </responsible_party>
  <keyword>psychosocial effects of cancer and its treatment</keyword>
  <keyword>recurrent childhood large cell lymphoma</keyword>
  <keyword>recurrent childhood lymphoblastic lymphoma</keyword>
  <keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
  <keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>atypical chronic myeloid leukemia, BCR-ABL negative</keyword>
  <keyword>blastic phase chronic myelogenous leukemia</keyword>
  <keyword>childhood acute lymphoblastic leukemia in remission</keyword>
  <keyword>childhood acute myeloid leukemia in remission</keyword>
  <keyword>childhood chronic myelogenous leukemia</keyword>
  <keyword>chronic myelomonocytic leukemia</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>juvenile myelomonocytic leukemia</keyword>
  <keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
  <keyword>recurrent childhood acute myeloid leukemia</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>childhood myelodysplastic syndromes</keyword>
  <keyword>primary myelofibrosis</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>disseminated neuroblastoma</keyword>
  <keyword>myelodysplastic/myeloproliferative neoplasm, unclassifiable</keyword>
  <keyword>previously treated childhood rhabdomyosarcoma</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>recurrent childhood rhabdomyosarcoma</keyword>
  <keyword>recurrent neuroblastoma</keyword>
  <keyword>recurrent ovarian germ cell tumor</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Neuroblastoma</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

